Literature DB >> 5344096

Purified protoplasmic peptides of mycobacteria: isolation of species-specific peptides from protoplasm of mycobacteria.

R E Beam, K D Stottmeier, G P Kubica.   

Abstract

Infections with mycobacteria other than tubercle bacilli are responsible for a variable percentage of cross-reactions to tuberculin. Two major suggestions for circumventing this problem have been made: the first, development of a quantitative tuberculin test, is based on the fact that most cross-reactions are smaller than those caused by true tuberculous infections; the second, preparation of purified skin test antigens from other mycobacteria, is based on the hope that greater specificity will be displayed by homologous sensitin. Effort so far has been focused on the culture filtrates as the source of antigen. This article describes the preparation of low molecular weight purified protoplasmic peptides (PPP) of specificity and sensitivity superior to purified protein derivatives.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5344096      PMCID: PMC315377          DOI: 10.1128/jb.100.1.195-200.1969

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  12 in total

1.  Skin reactions produced in rabbits by cell walls and protoplasm of Mycobacterium tuberculosis and M. butyricum.

Authors:  C L LARSON; E RIBI; W C WICHT; R LIST
Journal:  Am Rev Respir Dis       Date:  1961-02

2.  Studies on tuberculin active peptide. I. The isolation, crystallization and properties of tuberculin active peptide from tubercle bacillus.

Authors:  S MORISAWA; A TANAKA; K SHOJIMA; Y YAMAMURA
Journal:  Biochim Biophys Acta       Date:  1960-02-26

3.  Epidemiologic studies of tuberculin sensitivity. I. Preliminary results with purified protein derivatives prepared from atypical acid-fast organisms.

Authors:  L B EDWARDS; C E PALMER
Journal:  Am J Hyg       Date:  1958-09

4.  New aspects of mycobacterial skin tests. VI. Epidemiologic evaluation of tuberculin skin testing antigens in animal and human populations with known multiple infections.

Authors:  J Vakilzadeh; H Mac Vandiviere; I G Melvin; H S Willis
Journal:  Arch Environ Health       Date:  1968-06

5.  Investigation of protoplasmic extracts of tubercle bacilli as skin test antigens.

Authors:  J M Counts; G P Kubica
Journal:  Can J Microbiol       Date:  1968-10       Impact factor: 2.419

6.  A comparison of the ability of protoplasm and culture filtrate (PPD) antigens from Mycobacterium tuberculosis, M. kansasii and M. batteyi to elicit delayed reactions in infected guinea pigs.

Authors:  C L Larson; R E Baker; M B Baker
Journal:  Am Rev Respir Dis       Date:  1968-12

7.  Differential identification of mycobacteria. II. Subgroups of Groups II and 3 (Runyon) with different clinical significance.

Authors:  D G Kestle; V D Abbott; G P Kubica
Journal:  Am Rev Respir Dis       Date:  1967-06

8.  Preparation of highly immunogenic ribosomal fractions of Mycobacterium tuberculosis by use of sodium dodecyl sulfate.

Authors:  A S Youmans; G P Youmans
Journal:  J Bacteriol       Date:  1966-06       Impact factor: 3.490

9.  Chemical and serological relationships between the heteropolysaccharides of Mycobacterium tuberculosis and Mycobacterium kansasii.

Authors:  S E Birnbaum; L F Affronti
Journal:  J Bacteriol       Date:  1968-02       Impact factor: 3.490

10.  Cutaneous reactions to unclassified mycobacterial antigens. A study of children in household contact with patients who excrete unclassified Mycobacteria.

Authors:  J S CHAPMAN; H J DEWLETT; W E POTTS
Journal:  Am Rev Respir Dis       Date:  1962-10
View more
  11 in total

1.  Purified protoplasmic peptides of mycobacteria: chemical composition of a tuberculin-active glycopeptide.

Authors:  K D Stottmeier; R E Beam; H L David; R Shapira; D C Farshy
Journal:  J Bacteriol       Date:  1971-01       Impact factor: 3.490

2.  Comparison of antigens in sonic and pressure cell extracts of Mycobacterium tuberculosis.

Authors:  B W Janicki; G L Wright; R C Good; S D Chaparas
Journal:  Infect Immun       Date:  1976-02       Impact factor: 3.441

Review 3.  Mycobacterial antigens: a review of their isolation, chemistry, and immunological properties.

Authors:  T M Daniel; B W Janicki
Journal:  Microbiol Rev       Date:  1978-03

4.  Characterization and comparison of mycobacterial antigens by two-dimensional polyacrylamide gel electrophoresis.

Authors:  G L Wright; L F Affronti; M Reich
Journal:  Infect Immun       Date:  1972-04       Impact factor: 3.441

5.  Ribosomes of acid-fast bacilli: immunogenicity, serology, and in vitro correlates of delayed hypersensitivity.

Authors:  R E Baker; W E Hill; C L Larson
Journal:  Infect Immun       Date:  1973-08       Impact factor: 3.441

6.  Delayed hypersensitivity reactions provoked by ribosomes from acid-fast bacilli: physical characteristics and immunological aspects of core ribosomal proteins from Mycobacterium smegmatis.

Authors:  R V Loge; W E Hill; R E Baker; C L Larson
Journal:  Infect Immun       Date:  1974-03       Impact factor: 3.441

7.  Purified protoplasmic peptides of mycobacteria: in vivo and in vitro comparison of the species specificity of purified protoplasmic peptides and purified protein derivatives of mycobacterial culture filtrates.

Authors:  K D Stottmeier; R E Beam; G P Kubica
Journal:  J Bacteriol       Date:  1969-10       Impact factor: 3.490

8.  Separation of mycobacterial soluble antigens by isoelectric focusing.

Authors:  R G Moulton; T M Dietz; S Marcus
Journal:  Infect Immun       Date:  1971-03       Impact factor: 3.441

9.  Delayed hypersensitivity reactions provoked by ribosomes from acid-fast bacilli. I. Ribosomal isolation, characterization, delayed hypersensitivity, and specificity.

Authors:  R E Baker; W E Hill; C L Larson
Journal:  Infect Immun       Date:  1972-09       Impact factor: 3.441

10.  Cytoplasmic antigens from Nocardia elicting a specific delayed hypersensitivity.

Authors:  L Ortiz-Ortiz; M F Contreras; L F Bujalil
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.